Date: 16 October 2015
VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:
- A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
- Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
- Activity against azole-resistant fungal species.
- Low propensity for P450 drug-drug interactions.
Copyright: n/a
Notes: n/a
Images library
-
Title
Legend
-
Image D & E. A case of onychomycosis associated with Aspergillus ochraceopetaliformis as described in Nail infection by Aspergillus ochraceopetaliformis. Med Mycol. 2009 Mar 9:1-5, 2009, Brasch J, Varga J, Jensen JM, Egberts F & Tintelnot K
, 
, 
, 
, 
-
Further details
Image 5. Oral itraconazole pulse therapy was given to the patient (200 mg twice daily for 1 week, with 3 weeks off between successive pulses, for four pulses) and treatment was successful.
, 
, 
, 
, 
-
This patient was 28 yr old with adult lymphocytic leukaemia. She received induction chemotherapy and this infection developed 2 days after recovering from neutropenia.
, 
, 
, 
, 
, 
, 
, 
, 
, 
-
Close-up image of the lesion on the left thigh showing a mat of hyphae over the wound.
-
Eosinophilic mucin with A. flavus in the nasal cavity. Irregular crust of 2.5 cm from a patient diagnosed as allergic fungal sinusitis. Patient with allergic fungal sinusitis
-
GMS stain of eosinophilic mucin reveals a darkly stained dichotomously branched A. flavus hyphae within cellular background. Patient with allergic fungal sinusitis
-
4 Total obstruction of the sinuses due to inflamed mucosa. (Patient 04)
){kind=link}